Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-23-003437
Filing Date
2023-05-15
Accepted
2023-05-15 16:10:49
Documents
49
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q titanpharma_10q.htm   iXBRL 10-Q 474353
2 EXHIBIT 10.18 titanpharma_ex10-18.htm EX-10.18 11548
3 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 15318
4 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 7097
  Complete submission text file 0001829126-23-003437.txt   2896987

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ttnp-20230331.xsd EX-101.SCH 22364
6 XBRL CALCULATION FILE ttnp-20230331_cal.xml EX-101.CAL 38907
7 XBRL DEFINITION FILE ttnp-20230331_def.xml EX-101.DEF 81504
8 XBRL LABEL FILE ttnp-20230331_lab.xml EX-101.LAB 213828
9 XBRL PRESENTATION FILE ttnp-20230331_pre.xml EX-101.PRE 164387
43 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10q_htm.xml XML 355957
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 23922305
SIC: 2836 Biological Products, (No Diagnostic Substances)